Optimal Treatment with Boceprevir. Michael Manns

Similar documents
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors

SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano

How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy

Protease inhibitor based triple therapy in treatment experienced patients

Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?

47 th Annual Meeting AISF

Clinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.

CURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA

Express Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011

Introduction. The ELECTRON Trial

Hepatitis C Treatment 2014

Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona

HCV Case Study. Treat Now or Wait for New Therapies

Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine

Triple therapy with telaprevir or boceprevir: management of side effects

Predictors of Response to Hepatitis C Therapy in the DAA Era. Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid

Efficacy and safety of protease inhibitors for sever hepatitis C recurrence after liver transplantation: a first multicentric experience

Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors

Case #1. Case #1. Case #1: Audience vote VS. The Great Debate: When to Treat HCV in our HIV coinfected patients

Treatment of chronic hepatitis C in drug-naïve patients

Treatment of genotype 4 patient. with cirrhosis. Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble

How do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu

Antiviral treatment in HCV cirrhotic patients on waiting list

Experience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona

Oral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside

BOCEPREVIR (BOC): EVIDENCE FROM TRIALS

Why make this statement?

Personalised Treatment with Telaprevir in Graham R Foster Professor of Hepatology Queen Marys University of London

Treating HCV Genotype 2 & 3

New Therapeutic Strategies: Polymerase Inhibitors

New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD

ةي : لآا ةرقبلا ةروس

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients

Virological Tools and Monitoring in the DAA Era

Infection with hepatitis C virus (HCV) is a global health concern,

Hepatitis C Therapy Falk Symposium September 20, 2008

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

Les Inhibiteurs de Protéase du VHC

Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial

Treating now vs. post transplant

ABCs of Hepatitis C: What s New. The Long-Awaited New Era: Protease Inhibitors for HCV Genotype 1

The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients

Program Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.

Treatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona

HCV disease: treatment or deferral? Antonio Craxì Gastroenterologia & Epatologia, Di.Bi.M.I.S., Università di Palermo

TREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING. Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona

Optimal ltherapy in non 1 genotypes:

Interferon-based and interferon-free new treatment options

Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of

HCV In 2015: Maximizing SVR

Saeed Hamid, MD Alex Thompson, MD, PhD

New developments in HCV research and their implications for front-line practice

Associate Professor of Medicine University of Chicago

Emerging Approaches for the Treatment of Hepatitis C Virus

Olysio (simeprivir) Policy Number: Last Review: 09/2017 Origination: 09/2013 Next Review: 09/2018

Month/Year of Review: November 2011 End date of literature search: 4 th Quarter alone

VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES

DAA-based treatment in cirrhotic and post-transplanted patients. Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France

Treatment with the New Direct Acting Antivirals for Hepatitis C

Current Treatments for HCV

Current Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany

Disclosures 29/09/2014. Genetic determinants of. HCV treatment outcome. IDEAL: IL28B-type is the strongest pre-treatment predictor of SVR

The HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany

Global Hepatitis Programme. Guideline development for Hepatitis C virus Screening, Care and Treatment in low- and middle-income countries

Treating HCV After Liver Transplantation: What are the Treatment Options?

Pegylated Interferon Agents for Hepatitis C

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)

Best of AASLD 2010 For IAGH. April 2011 Reza Malekzadeh M.D. AGAF Professor of Medicne DDRC/TUMS

Treatments of Genotype 2, 3,and 4: Now and in the future

Michael Fried, MD University of North Carolina Chapel Hill, NC. Ira Jacobson, MD Weill Cornell Medical College New York, NY

Review Article Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy

What is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago

29th Viral Hepatitis Prevention Board Meeting

C-HEP Meeting 2012 Controversies in the Management of Viral Hepatitis. 19. October Berlin

Pivotal New England Journal of Medicine papers 2014 Phase 3 Trial data

Identifying Subgroups in Product Labeling: 2 Recent Case Studies. Martin King AbbVie

ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT

Hepatitis C in Special Populations

Transformation of Chronic Hepatitis C Treatment

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)

IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE?

From 19 February 2015

Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1

EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

Azienda ULSS12 Veneziana

For the RESPOND-2 Investigators

DAAs in the era of decompensated liver disease. Piero L. Almasio University of Palermo

HCV Treatment in 2016: is there still a role for IFNa and ribavirin?

Expert Perspectives: Best of HCV from EASL 2015

Hepatitis C en 2013 Tratar o Esperar? Vicente Soriano Servicio de Enfermedades Infecciosas Hospital Carlos III Madrid

Stick or twist management options in hepatitis C

Highlights of AASLD 2012 CCO Official Conference Coverage of the 2012 Annual Meeting of the American Association for the Study of Liver Diseases

Treatment Targets HCV Genotype 1 & PIs Treating HCV G2&3 Future Therapies. Advances in treatment of HCV Dr John F Dillon

HEPATITIS C. Mitchell L. Shiffman, MD, FACG Director. Liver Institute of Virginia. Richmond and Newport News, VA

SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES

Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir

NS5A inhibitors: ideal candidates for combination?

Personalizzazione della Cura in Epatologia. Epatite Cronica C: Pazienti con Genotipo 2

Management of HCV in Decompensated Liver Disease

Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA

Transcription:

Optimal Treatment with Boceprevir Michael Manns 6th Paris Hepatitis Conference, 14th January 2013

Acknowledgements Benjamin Maasoumy

Optimal Patient Selection Defining the Ideal Candidate Treatment Urgency Chances for SVR Safety Profile Maasoumy and Manns, Liver International 2013

Optimal Patient Selection Defining the ideal Candidate Chances for SVR Treatment Urgency Null Responder, liver cirrhosis Safety Profile In the real world there may even occur additional, nonmedical factors that interfere with aim to initiate treatment i.e. professional drivers, social reasons, poor compliance, patient wish

Optimal Patient Selection Real Life Safety of Triple Therapy CUPIC Week 16 MHH Week 12 (+/- Personalized lead-in) Patient number 497 86 609 SAEs (% of patients affected) 40% 19% 14% Death - due to Infection 6 (1.2%) 50% 1 (1.2%) 100% 3 (0.5%) 100% EAP Week 16 Anemia Dose reduction EPO 12% 51% 36% 0% 28% 24% Blood Transfusion 12% 14% 12% Predictors for SAEs: CUPIC MHH Platelets <100.000/nl Platelets <110.000/nl (SAE rate 48%) Albumin <35g/l Child-Pugh Score >5 (SAE rate 45%) EAP: Patients with advanced cirrhosis were not included may explain lower rate of SAEs Maasoumy et al, AASLD 2012; PLoS One 2013 in press Colombo et al., AASLD 2012; Hezode et al., AASLD 2012;

Optimal Patient Selection Defining the ideal Candidate Ideal Candidate Treatment Urgency (F2/)F3 fibrosis early cirrhosis Chances for SVR Safety Profile No significant Co-Morbidities Previous Relapser Treatment naïve Things may not be that easy in many cases!

Optimal Patient Selection Real Life Eligibility for Triple Therapy 208 patients with chronic HCV GT1 infection referred to hepatitis outpatient clinic of Hannover Medical School between June 1st and November 30th 2011 were evaluated for triple therapy Real Life Phase-3 trials: F3/F4: 64%; platelets <90/nl: 16%, treatment-experienced: 60% Therapyassociated Safety Concerns Poor Chance for SVR Decision: No Triple Therapy n=103 Regularly multiple reasons influenced the final decision Almost 50% (n=103) not treated Low Treatment Urgency: Wait for better Options Nonmedical Patient related Reasons: i.e. Patients Wish Real Life Maasoumy et al, PLoS One 2013 in press; AASLD 2012

Treatment Duration Optimal Patient Selection Telaprevir vs. Boceprevir Telaprevir RGT possible for Relapsers Boceprevir Co-Infections Some efficacy in GT2 Some efficacy in GT3

Telaprevir has some antiviral efficacy against HCV genotype 2 but not against genotype 3 Genotype 2 Genotype 3 Telaprevir Monotherapy Telaprevir Monotherapy Foster G et al, Gastroenterology 2011

Boceprevir has some antiviral efficacy against HCV genotype 2 and genotype 3 4 pts. Genotype 3 2 pts. Genotype 2 Silva M et al, APASL 2011

Optimal Patient Selection Telaprevir vs. Boceprevir Telaprevir Boceprevir Treatment Duration RGT possible for Relapsers Co-Infections Some efficacy in GT2 Some efficacy in GT3 Lower PI Costs In Null Responders and Cirrhotics (if treatment is not discontinued) Naïve patients In cases of treatment discontinuation

PI costs (in ) PI Treatment costs Telaprevir Boceprevir 36 463 36 463 36 463 36 463 31 894 31 894 23 920 12.543 43 855 7.421 Boceprevir Telaprevir Naive Naive_RGT Relapser/PR Cirrhotics/NR Boceprevir PI treatment costs per month lower: 3.987 vs. 12.154 Boceprevir cheaper in cases of early treatment failure Sarrazin et al, Z Gastro 2012

Optimal Patient Selection Ideal Candidate for Boceprevir Treatment-naïve Co-infected with HCV GT3 and Patients that benefit from a Lead-In

Optimal Treatment Design Lead-In a controversial debate Pro Contra

SVR Optimal Treatment Design Lead-In Virological data 70% 60% 50% 66% 66% 60% 64% No significant differences 40% 30% Lead-In 20% no Lead-In 10% 0% SPRINT-1 (BOC) REALIZE (TVL) Zeuzem et al., NEJM 2011 Kwo et al., Lancet 2010

Optimal Treatment Design Lead-In a controversial debate Not every Patient requires a PI On-Treatment Risk/Benefit evaluation Uncertain Response to previous Therapy Uncertain Tolerance Pro Contra Lead-In as a test phase important tool used to gain additional information

Lead-in in easy to treat patients Not every patient benefits from a PI Vierling et al., EASL 2011 Poordad et al., NEJM 2011

P/R = P/R/PI? A randomized trial - Study Design 179 treatment-naïve patients with chronic HCV GT1 infection and a LVL (<600,000 IU/ml) /+ BOC 24w / 4w / 20w Patients with HCV RNA BLOD (48%) randomized into 2 arms (1:1) Pearlman et al, AASLD 2012

P/R = P/R/PI? A randomized trial - Results SVR - Overall - IL28B CC non-cc - GT 1a 1b P/R/BOC n=41 90% 96% 79% 81% 96% P/R n=38 89% 96% 77% 85% 92% p-values 0.8 0.51 0.72 ns ns Relapse rates 3% 6% 0.52 Dose reductions 32% 29% ns Discontinuations 7% 5% ns Pearlman et al, AASLD 2012

Optimal Patient Selection Ideal Candidate for Boceprevir Treatment-naïve Co-infected with HCV GT3 Patients that benefit from a Lead-In Easy-to-treat patients Patients with uncertain virological outcome Lead-In also possible for Telparevir not well established! Patients with uncertain treatment tolerance

Optimal treatment with boceprevir Finding the optimal treatment design Lead-in? RGT vs. fixed duration Regimens for treatmentexperienced patients Stopping criteria

Optimal Treatment Design Response Guided Treatment SPRINT-2 study: Phase 3 trial with 1097 treatment-naïve patients. Poordad et al., NEJM 2011

SVR Optimal Treatment Design Response Guided Treatment SPRINT-2 RGT Fixed (48w) 96% 96% 63% 66% 67% 67% 42% 52% All Patients F0-F2 F3/F4 ervr Decision by FDA and EMA: RGT for treatment-naïve, non-cirrhotic patients Patients with ervr - End treatment after 28 weeks - Just like in the SPRINT-2 trial Those without ervr - not directly studied!!! - Recommended regimen SPRINT-2 - Non-eRVR patients considered to be a mixture of PR and NR - Treated like non-ervr patients in RESPOND-2 (4w P/R; 32 w P/R/BOC; 12w P/R) Poordad et al., NEJM 2011

Optimal Treatment Design Response Guided Treatment Respond-2 study: Phase 3 trial with 403 partial responders or relapsers. Null responders excluded!! Bacon et al., NEJM 2011

Optimal Treatment Design Response Guided Treatment RESPOND-2 59% RGT 66% 66% 68% 68% 44% Fixed 48w 75% 69% 40% 52% 86% 88% All Patients F0-F2 F3/F4 Relapser Partial Responder ervr Decision by: FDA: no significant difference in non-cirrhotics with ervr Bacon et al., NEJM 2011 RGT possible in non-cirrhotic Relapsers and PR Same regimen like in the RESPOND-2 trial EMA: no RGT!!! All non-cirrhotic Relapsers and PR should be treated for 48 weeks (4w LI; 32w P/R/BOC; 12w P/R)

Optimal Treatment Design RGT in Relapsers and PR the EMA approach FDA Patients with undetectable HCV RNA W8 Group 2: RGT Group 3: fixed Relapse *8/71 (11%) *6/80 (8%) SVR 64/74 (86%) 74/84 (88%) *In a few patients without FU24 data SVR12 data were used EMA Rationale: Patients in both groups were treated the same way until week 36 Thus analysis should exclude those who dropped out before this stage!!!!! EMA Patients with undetectable HCV RNA W8 Group 2: RGT Group 3: fixed Relapse *7/69 (10%) *0/71 (0%) SVR 63/71 (89%) 71/73 (97%) No RGT due to seven Relapses in the RGT arm! EMA Victrelis assement report

Optimal Treatment Design Cirrhotics and null responders Cirrhotics: -Data on efficacy in cirrhotics are limited - RESPOND-2: 39 cirrhotic patients; SVR: 35% (RGT) vs. 77% (fixed) - SPRINT-2: 40 cirrhotic patients; SVR: 31% (RGT) vs. 42% (fixed) -Overall, less favorable outcome -Recommendation: 4 weeks lead-in and 44 weeks triple therapy if tolerated - If AEs i.e. anemia is challenging dual therapy (P/R) in the last 12 weeks can be considered Null Responder: -not studied in the pivotal trials! -Indirect analysis by considering those with a poor lead-in response comparable to previous null responders -Recommendation: difficult-to treat cohort; 4 weeks lead-in and 44 weeks triple therapy EMA Victrelis assement report Bacon et al., NEJM 2011; Poordad et al., NEJM 2011

Boceprevir in null-responders PROVIDE-Study - Efficacy 164 patients treated with P/R/BOC previously experienced a treatment failure with P/R in a BOC phase 2/3 control arm Bronowicki et al., EASL 2012

Optimal Treatment Design Recommended Design Treatment-naïve //Boceprevir //Boceprevir / FDA Partial Responders/ Relapsers //Boceprevir //Boceprevir / EMA //Boceprevir / Null Responders/ Cirrhotics //Boceprevir Weeks 0 4 8 12 24 28 36 48 Victrelis Prescribing information EMA Victrelis Prescribing information FDA

Optimal Treatment Design RGT - Personalized Approaches Based on the risk/benefit ratio personalized approaches may be applied i.e. -Dual therapy for treatment-naïve patients with RVR -PR and relapsers with ervr: risk of AEs vs. small chance for a relapse (10%) -Null Responders and cirrhotics with ervr: Lack of data Maasoumy and Manns, Liver international 2013

Optimal Treatment Design Some Personalized Approaches Treatment-naïve //Boceprevir //Boceprevir / FDA Partial Responders/ Relapsers //Boceprevir //Boceprevir / EMA //Boceprevir / Null Responders/ Cirrhotics //Boceprevir // Boceprevir Weeks 0 4 8 12 24 28 36 48 *Personalized EMA Decision based on seven patients Lack of data for null responders/cirrhotics Room for personalized approaches: Shortening of treatment, if ervr and poor P/R/BOC tolerability Shortening of treatment or P/R only, if poor (P/R/)BOC tolerability *decision based on personalized risk/benefit ratio Maasoumy and Manns, Liver International 2013

Optimal Treatment Design Some Personalized Approaches Treatment-naïve //Boceprevir //Boceprevir / FDA Partial Responders/ Relapsers //Boceprevir //Boceprevir / EMA //Boceprevir / Null Responders/ Cirrhotics //Boceprevir // Boceprevir Weeks 0 4 8 12 24 28 36 48 Futility Rules Label *Personalized <1log decline Null responder + cirrhotic <3log decline HCV-RNA 100 IU/ml HCV-RNA > LLD *decision based on personalized risk/benefit ratio *Personalized Shortening of treatment, if ervr and poor P/R/BOC tolerability Shortening of treatment or P/R only, if poor (P/R/)BOC tolerability Maasoumy and Manns, Liver International 2013

Optimal Treatment for Boceprevir Every Single Step is essential!! Optimal Patient Selection Optimal Dosing Optimal Treatment Design Lead-In Treatment Duration - RGT Management of Drug-Drug- Interactions Management of Adverse Events Optimal Treatment

Thank you for your attention!!